MARATTO

article · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

20166.3k citationsOpen accessDebre Berhan University

In plain language

A global study of 32 cancer groups across 195 countries and territories from 1990 to 2015 reveals a rising global cancer burden. In 2015, there were 17.5 million cancer cases and 8.7 million deaths worldwide. Between 2005 and 2015, cancer cases increased by 33 percent, driven primarily by population ageing and growth. For men, prostate cancer was the most common diagnosis, while tracheal, bronchus, and lung cancer caused the most deaths. For women, breast cancer was both the most common and the leading cause of cancer death. Although age-standardised death rates decreased in 140 countries, countries experiencing increases in these death rates were predominantly located on the African continent. The findings highlight the growing strain on healthcare resources and emphasise the critical need for localised resource allocation and targeted cancer prevention programmes.

Key takeaways

  • Global cancer cases reached 17.5 million in 2015, representing a 33 percent increase since 2005 that was driven largely by population ageing and growth.
  • Prostate cancer was the most common cancer in men, while breast cancer was the most common and deadly cancer in women globally.
  • Although age-standardised death rates for cancer decreased in 140 countries between 2005 and 2015, countries with rising death rates were mostly located in Africa.
  • Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths and disability-adjusted life-years for men globally.

Why it matters

Understanding the shifting global and regional burden of cancer is essential for effective healthcare planning. As populations age and grow, cancer incidence is expected to rise, placing immense pressure on healthcare systems. This research highlights where resources are most urgently needed for prevention, early diagnosis, and treatment, particularly in regions like Africa where cancer death rates are rising.

Commercialisation angle

The abstract does not indicate an application pathway for this research.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

IMPORTANCE: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. OBJECTIVE: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. EVIDENCE REVIEW: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates were multiplied by disability weights. The YLLs were estimated by multiplying age-specific cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs and YLLs. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to summarize results. FINDINGS: In 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths. Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing 16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the most common cancer globally was prostate cancer (1.6 million cases). Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths and DALYs in men (1.2 million deaths and 25.9 million DALYs). For women, the most common cancer was breast cancer (2.4 million cases). Breast cancer was also the leading cause of cancer deaths and DALYs for women (523 000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates for all cancers combined increased in 174 of 195 countries or territories. Age-standardized death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195 countries or territories. Countries with an increase in the ASDR due to all cancers were largely located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased significantly for Hodgkin lymphoma (-6.1% [95% uncertainty interval (UI), -10.6% to -1.3%]). The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic myeloid leukemia, although these results were not statistically significant. CONCLUSION AND RELEVANCE: As part of the epidemiological transition, cancer incidence is expected to increase in the future, further straining limited health care resources. Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study results demonstrate that progress is possible in the war against cancer. However, the major findings also highlight an unmet need for cancer prevention efforts, including tobacco control, vaccination, and the promotion of physical activity and a healthy diet.

Research topics

  • Global Cancer Incidence and Screening
  • Multiple and Secondary Primary Cancers
  • Frailty in Older Adults

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1001/jamaoncol.2016.5688

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.